CA Patent

CA2539309A1 — Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Assigned to Aventis Pharma SA · Expires 2005-03-31 · 21y expired

What this patent protects

Solvat acétonique du diméthoxy docétaxel ou (2R,3S)-3-tert-butoxycarbonylami no- 2-hydroxy-3-phényl- propionate de 4-acétoxy-2.alpha.-benzoyloxy-5.beta.,20- époxy-1-hydroxy-7.beta.,10.beta.-diméthoxy-9- oxo-tax-11-ène-13.alpha.-yle e t sa préparation par cristallisation à partir …

USPTO Abstract

Solvat acétonique du diméthoxy docétaxel ou (2R,3S)-3-tert-butoxycarbonylami no- 2-hydroxy-3-phényl- propionate de 4-acétoxy-2.alpha.-benzoyloxy-5.beta.,20- époxy-1-hydroxy-7.beta.,10.beta.-diméthoxy-9- oxo-tax-11-ène-13.alpha.-yle e t sa préparation par cristallisation à partir d'une solution hydro-acétonique.

Drugs covered by this patent

Patent Metadata

Patent number
CA2539309A1
Jurisdiction
CA
Classification
—
Expires
2005-03-31
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.